Skip to main content

14-02-2021 | ASCO GU 2021 | Conference coverage | Video

Pembrolizumab, SABR develop a RAPPORT for oligometastatic RCC

Shankar Siva provides an overview of the RAPPORT study of pembrolizumab plus stereotactic ablative body radiotherapy for the treatment of renal cell carcinoma with oligometastases (3:07).

Read transcript